Managers

Fund Performance: UTIMCO venture portfolio, vintages 2012 to 2014

August Top 10s: Venture continues consolidation into fewer, larger deals

Boston Scientific agrees to buy VC-backed Augmenix for up to $600 mln

Boston Scientific has agreed to acquire Waltham, Massachusetts-based Augmenix, which develops radiation oncology products to treat prostate cancer. The deal includes $500 million in cash, and up to $100 million based on milestones. Augmenix, previously known as SpaceOAR and founded in 2008, had raised funding from Excelestar Ventures, Ascension Health Ventures, Catalyst Health Ventures, Pinnacle Ventures and the Sparta Group.

MissionOG gathers $60.9 mln for sophomore fund

Philadelphia-based MissionOG, an early-to-growth stage venture firm, has raised $60.9 million for its second fund, according to an SEC filing. The target is $100 million.

Khosla Ventures backs Scipher Medicine

Waltham, Massachusetts-based Scipher Medicine, a developer of a molecular technology platform that can predict if a patient will actually respond to a particular drug therapy has closed its latest funding, raising a total tally of $10 million. Khosla Ventures led the latest round.

Rise of the rest is 'greatest arbitrage' of a lifetime, says Steve Case

Fitness funding, led by Peloton plan for IPO, has investors pumped

Aramco considering $1 bln tech venture fund: WSJ

Aramco, Saudi Arabia's national oil company, is considering a $1 billion venture fund that will invest in international technology firms, according to the Wall Street Journal. The news outlet also reported that Aramco is contemplating opening an office in Silicon Valley or "elsewhere in the U.S. to generate deals."

4DMT reels in $90 mln Series B

4D Molecular Therapeutics, a gene therapy company, has raised $90 million in Series B Financing. Viking Global Investors led the round with participation from ArrowMark Partners, Janus Henderson Investors, The Biotechnology Value Fund, MiraeAsset Financial Group, Pappas Capital & Chiesi Ventures, Pfizer Ventures, Perceptive Advisors, Ridgeback Capital Investments, CureDuchenne Ventures and Berkeley Catalyst Fund.

Notable Health scores $13.5 mln Series A

San Mateo, California-based Notable Health, an artificial intelligence-powered healthcare company that automates and digitizes physician-patient interactions, has raised $13.5 million in Series A funding. F-Prime Capital Partners and Oak HC/FT led the round with participation from return backers Greylock Partners and Maverick Ventures. F-Prime Capital Partners’ General Partner Carl Byers will join Notable Health’s board of directors while Oak HC/FT Managing Partner Annie Lamont will serve as a board observer.